Marksans Pharma gains after its arm gets marketing authorization for Metformin Hydrochloride 500mg/ 5 ml Oral Solution
Marksans Pharma is currently trading at Rs 260.60, up by 0.25 points or 0.10% from its previous closing of Rs 260.35 on the BSE.
The scrip opened at Rs 260.40 and has touched a high and low of Rs 265.00 and Rs 258.70 respectively. So far 91142 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 1 has touched a 52-week high of Rs 358.50 on 05-Dec-2024 and a 52-week low of Rs 130.15 on 04-Jun-2024.
Last one week high and low of the scrip stood at Rs 265.00 and Rs 244.10 respectively. The current market cap of the company is Rs 11847.97 crore.
The promoters holding in the company stood at 43.87%, while Institutions and Non-Institutions held 26.76% and 29.37% respectively.
Marksans Pharma’s wholly owned subsidiary -- Relonchem has received marketing authorization for the product Metformin Hydrochloride 500mg/ 5 ml Oral Solution from UK Medicines & Healthcare Products Regulatory Agency.
Earlier, Relonchem had received marketing authorization for the product Sennosides 7.5 mg Tablets from UK Medicines & Healthcare Products Regulatory Agency.
Marksans Pharma is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets.
